Insider · CIK 0001771207
Lorenz Muller
Files at MIST (Milestone Pharmaceuticals Inc.). First filing Jan 28, 2026, latest Jan 28, 2026.
In brief
Lorenz Muller files SEC Form 4 as officer at MIST (Milestone Pharmaceuticals Inc.). Since Jan 28, 2026, Lorenz Muller has reported 0 open-market buys worth $0 and 1 open-market sell worth $146k, the latest filed on Jan 28, 2026.
A track record needs three past buys with six months of prices behind them; Lorenz Muller has 0, so none is measured yet.
The newest scored trade: sold $146k of MIST on Dec 15, 2025, filed Jan 28, 2026, scored 36 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $146k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MIST: Milestone Pharmaceuticals Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Milestone Pharmaceuticals Inc. | $146k 64,746 shares | -26% | - |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 5, 2026 |
| Feb 2, 2026 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 4, 2026 |
| Feb 2, 2026 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Restricted Stock Unitderivative | +136,000 | $0.00 | $0 | 136,000 | Feb 4, 2026 |
| Dec 12, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Common Shares | +100,000 | - | - | 250,052 | Jan 28, 2026 |
| Dec 15, 2025 | MIST Milestone Pharmaceuticals Inc. | SOpen-market sale Common Shares | -53,566 | $2.32 | $124k | 196,486 | Jan 28, 2026 |
| Jan 26, 2026 | MIST Milestone Pharmaceuticals Inc. | MOption exercise Common Shares | +20,100 | - | - | 216,586 | Jan 28, 2026 |
| Jan 26, 2026 | MIST Milestone Pharmaceuticals Inc. | SOpen-market sale Common Shares | -11,180 | $1.93 | $22k | 205,406 | Jan 28, 2026 |
| Dec 12, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 28, 2026 |
| Jan 26, 2026 | MIST Milestone Pharmaceuticals Inc. | MOption exercise Restricted Stock Unitsderivative | -20,100 | $0.00 | $0 | 60,300 | Jan 28, 2026 |
| Dec 9, 2025 | MIST Milestone Pharmaceuticals Inc. | GGift Common Shares | -25,000 | $0.00 | $0 | 150,052 | Dec 11, 2025 |
| Jul 11, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Common Shares | +66,666 | - | - | 175,052 | Jul 15, 2025 |
| Jul 11, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Series A Common Warrants (right to buy)derivative | +66,666 | - | - | 66,666 | Jul 15, 2025 |
| Jul 11, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Series B Common Warrants (right to buy)derivative | +66,666 | - | - | 66,666 | Jul 15, 2025 |
Questions about Lorenz Muller
Answered from the filings on this page, as of the latest one.
Is Lorenz Muller buying or selling?
In the last 12 months Lorenz Muller reported 0 open-market buys worth $0 and 1 open-market sell worth $146k on SEC Form 4; the latest was sold $146k of MIST on Dec 15, 2025. Grants, option exercises and tax withholding are not counted.
How did Lorenz Muller's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lorenz Muller has 0.
Where does Lorenz Muller file Form 4?
Lorenz Muller has filed Form 4 at MIST (Milestone Pharmaceuticals Inc.) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.